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Abstract.
Background: Few adequately-powered studies have systematically evaluated brain morphology in adult-onset myotonic
dystrophy type 1 (DM1).
Objective: The goal of the present study was to determine structural brain differences between individuals with and without
adult-onset DM1 in a multi-site, case-controlled cohort. We also explored correlations between brain structure and CTG
repeat length.
Methods: Neuroimaging data was acquired in 58 unaffected individuals (29 women) and 79 individuals with DM1 (50
women). CTG repeat length, expressed as estimated progenitor allele length (ePAL), was determined by small pool PCR.
Statistical models were adjusted for age, sex, site, and intracranial volume (ICV).
Results: ICV was reduced in DM1 subjects compared with controls. Accounting for the difference in ICV, the DM1 group
exhibited smaller volume in frontal grey and white matter, parietal grey matter as well as smaller volume of the corpus
callosum, thalamus, putamen, and accumbens. In contrast, volumes of the hippocampus and amygdala were significantly
larger in DM1. Greater ePAL was associated with lower volumes of the putamen, occipital grey matter, and thalamus. A
positive ePAL association was observed for amygdala volume and cerebellar white matter.
Conclusions: Smaller ICV may be a marker of aberrant neurodevelopment in adult-onset DM1. Volumetric analysis revealed
morphological differences, some associated with CTG repeat length, in structures with plausible links to key DM1 symptoms
including cognitive deficits and excessive daytime somnolence. These data offer further insights into the basis of CNS disease
in DM1, and highlight avenues for further work to identify therapeutic targets and imaging biomarkers.
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INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a dom-
inantly inherited, multisystem disorder, resulting
from expansion of a CTG trinucleotide repeat in
the 3’-untranslated region of DMPK [1]. The clin-
ical phenotype is widely variable, with common
symptoms including skeletal muscle weakness and
myotonia, cataracts, cardiac conduction defects, and
male hypogonadism. Involvement of the CNS under-
lies additional symptoms such as cognitive deficits,
excessive daytime somnolence, apathy, and impaired
social functioning [2]. CNS symptoms are reported
frequently by patients [3], and may greatly impact
quality of life [4, 5], relationships with caregivers
[6] and engagement with medical care [7]. With
the advent of clinical trials of potential disease-
modifying therapies for DM1, expert working groups
have highlighted the need to improve understanding
of the mechanisms underlying CNS disease, both to
identify neuroimaging biomarkers and reveal poten-
tial targets for therapy [8, 9].
MRI studies in patients with DM1 have identified
morphometric abnormalities in the brain, includ-
ing global volume loss, ventricular dilation, white
matter lesions, and disruptions of white matter
microstructure evident in diffusion tensor imaging
[10]. According to several studies that used voxel-
based morphometry (VBM), global volume loss may
be driven by grey matter atrophy in the cerebral cor-
tex and subcortical structures [11–13]. Some VBM
studies have also demonstrated associations between
focal brain morphology and cognitive abilities [14,
15], and/or CTG repeat length [16, 17], although
others found no association [12, 13].
Several limitations of preceding neuroimaging
studies should be considered. First, previous stud-
ies have generally included fewer than 40 affected
individuals, limiting the power to detect meaning-
ful abnormalities in brain morphology [11, 13, 15,
18, 19]. Second, few studies have validated the
VBM findings with alternative approaches that enable
comprehensive exploration of global and regional
grey and white matter structural differences between
patients and controls [18]. Third, previous studies
have relied on traditional methods to measure CTG
repeat expansion which fail to take account of age-
dependent, expansion-biased mosaicism in somatic
cells [20]. Finally, some existing studies have com-
bined congenital DM1 (CDM), juvenile-onset DM1
(JDM), and adult-onset DM1 in a single sample [13,
17]. Individuals with CDM exhibit severe cogni-
tive delay [21], while those with adult-onset DM1
typically have much milder impairment [22]. The
diversity of CNS phenotypes in heterogeneous sam-
ples confounds analyses of structural correlations
further.
To address these limitations, we harmonized neu-
roimaging protocols across two sites to obtain a large,
homogeneous, case-controlled sample of individu-
als with adult-onset DM1. A volume-based brain
parcellation approach was applied to characterize
brain structures. Genotyping was conducted by small-
pool PCR (SP-PCR) to estimate the progenitor allele
length, which has been shown to improve clinical
correlations compared to traditional methods [23].
MATERIALS AND METHODS
Participants
Individuals with DM1 were recruited to the Uni-
versity of Iowa from across the United States via
advertisements through the Myotonic Dystrophy
Foundation (MDF) and word of mouth. Unaffected
participants were primarily recruited from the Iowa
City area via advertisements. Some were unaffected
spouses of affected participants. Recruitment took
place between September 2014 and July 2017.
In Glasgow, UK, individuals with DM1 attend-
ing the annual review at the West of Scotland
Clinical Genetics Service were invited to partici-
pate. Unaffected participants were recruited from
affected subjects’ families and from the Scottish
Health Research Register (www.registerforshare.org)
[24]. Participants in Glasgow were recruited between
January 2016 and May 2017.
Exclusion criteria for all participants were: learn-
ing disability in childhood, a history of serious
head injury, or a chronic neurological disorder other
than DM1. Unaffected participants were additionally
required to be without history of substance abuse,
psychiatric disease, or major medical disease, includ-
ing: heart disease, sleep disorder, vascular disease,
uncontrolled hypertension, cancer, diabetes mellitus,
lung disease, and autoimmune conditions.
Recruitment was targeted to adult-onset DM1 only.
The Glasgow site recruited only patients who denied
onset of DM1-specific symptoms before age 16,
while the Iowa site included participants who denied
symptoms before age 18. The sample included seven
individuals who had self-reported age of first onset
before age 18.
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Participants underwent genetic testing as part of
the research study. All participants recruited into the
DM1-affected group at the Glasgow site, and the
majority at the Iowa site (93%), had also undergone
genetic testing prior to participation and were aware
of their genetic status. A subset of participants in Iowa
were at-risk for DM1, but had not undergone predic-
tive testing (n = 11). At-risk individuals in the Iowa
sample who were determined to have CTG repeat
length >50 were included in the DM1 group (n = 4).
The remainder had CTG repeat lengths in the non-
disease associated range, and were included in the
control group (n = 7). Research staff, clinicians and
scientists involved in this study remained blind to the
genetic status of at-risk individuals. All data were
de-identified and all participants at the Iowa site con-
sented to non-disclosure of genetic results obtained
as part of the study. Control participants recruited in
Glasgow were not genotyped for CTG repeat length,
but none was at risk of DM1 by family history,
and none exhibited overt signs of any neurological
disorder. Control participants in Iowa were geno-
typed for CTG repeat length, to confirm unaffected
status.
All participants gave written, informed consent
prior to enrolling in the protocol in accordance to the
Declaration of Helsinki. The study was approved by
the University of Iowa’s Institutional Review Board
or the West of Scotland Research Ethics Committee
(Reference: WOS 15/WS/0189).
Muscle impairment rating scale (MIRS)
Severity of muscle weakness, expressed as muscle
impairment rating scale (MIRS) [25], was determined
by examination by a neurologist or other specialist
experienced in DM1.
Image acquisition
Iowa participants who participated before June
2016 (n = 52) were scanned using a 3T Siemens
Trio TIM (Siemens AG, Munich, Germany; 12-
channel head coil), and those who participated after
June 2016 (n = 27) were scanned on 3T General
Electric Discovery MR750w (GE Medical Sys-
tems, Chicago, IL, 16-channel head and neck coil).
Anatomical T1-weighted images were acquired as
follows for Siemens (GE parameters in parentheses):
coronal MPRAGE (BRAVO), TR = 2300 (8.392) ms,
TE = 2.82 (3.184) ms, TI = 900 (450) ms, flip angle =
10 (12)◦, FOV = 282 × 282 × 264 mm, matrix = 256
× 256 × 240. Parameters for T2-weighted images
were: coronal, TR = 4800 (3000) ms, TE = 430 (85.
925) ms, FOV = 256 × 256 × 224 mm, matrix = 256
× 256 × 160.
In Scotland, imaging was carried out on a 3T
Siemens Prisma MRI scanner (Software version:
VE11B. Erlangen, Germany, 20-channel head and
neck coil). T1-weighted parameters: coronal MPR
AGE, TR = 2300 ms, TE = 2.01 ms, TI = 900 ms, flip
angle = 10◦, FOV = 282 × 282 × 211 mm, matrix =
256 × 256 × 192. T2-weighted parameters coronal
SPACE, TR = 3200 ms, TE = 407 ms, FOV = 282 ×
198 × 194 mm, matrix = 256 × 180 × 176.
Image processing
Bias field inhomogeneity was corrected using the
N4 algorithm implemented in Advanced Normal-
ization Tools software [26]. Images were processed
using the BRAINSAutoWorkup pipeline which
optimizes tissue classification through an itera-
tive framework and produces robust parcellation
of brain regions in a multi-site setting [27].
BRAINSAutoWorkup labels brain regions using a
multi-atlas, similarity-weighted, majority-vote pro-
cedure (joint label fusion, [28]) using a set
of expert-segmented templates adapted from the
Desikan-Killiany atlas [29]. Brain regions include
cortical and subcortical regions, separated by hemi-
spheres and tissue type (gray or white matter)
where appropriate. Residual inter-scanner varia-
tion was harmonized using an empirical Bayesian
approach [30, 31] as implemented by the ez.combat
toolbox in R [32]. We confirmed that scanner
did not predict regional volume by conducting
Kolmogorov-Smirnov tests (Supplementary Table 1)
and visualizing the empirical cumulative distribu-
tions for each scanner across ROIs and groups
(Supplementary Figure 1). Statistical analyses were
performed on the harmonized neuroimaging data.
Measurement of CTG repeat length
Genotyping of CTG repeat in DM1 partici-
pants was completed by SP-PCR [33]. For each
patient, four reactions were completed, each using
300 pg blood genomic DNA template. CTG repeat
lengths were estimated by comparison against
DNA fragments of known length in the molecular
weight marker, using CLIQS software (TotalLabs
UK Ltd.). The lower boundary of the expanded
molecules in SP-PCR was used to estimate the
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inherited or progenitor allele length (ePAL) [34],
which is the major determinant of age at symptom
onset [23].
Statistical analyses
It is important to account for intracranial vol-
ume (ICV) when comparing regions between groups,
because regions scale with ICV. The goal of cor-
rection is to transform the region of interest (ROI)
such that it is no longer related to ICV, which
requires accounting for non-linear relationships. The
power-proportion method (PPM) divides volume by
, where  is estimated from a non-linear regres-
sion model, ROI =ICV [35]. We estimated  for
each ROI, and divided ROI by ICV. Each ratio
was subsequently standardized by subtracting out the
grand mean, and dividing by the SD. The efficacy
of detrending was checked by running linear regres-
sion models predicting the adjusted ROI from ICV.
None of the estimates were statistically significant
(unadjusted, lowest p-value = 0.647; see Supplemen-
tary Figure 2).
The multivariable linear regression models to
examine group differences included the harmonized,
standardized, PPM-adjusted ROI volumes as the
dependent variable, and group, age, sex, and site as
predictors:
Zi =0 + 1 groupi + 2 agei+ 3 sexi+ 4 sitei + ei,
In this equation, Zi is the adjusted ROI volume for
the ith participant (i = 1, . . . , N). Group, sex, and site
were expressed as numeric factors. It was assumed
that the ei were normally distributed with zero mean
and non-zero variance.
The models for ePAL considered only the DM1
group:
Zi =0 + 1 ePALi+ 2 agei+ 3 sexi+ 4 sitei + ei,
Group and ePAL estimates are presented as
adjusted means normalized to the standard deviation.
Inference was based on the 99% confidence interval
(CI).
RESULTS
Sample
The pooled sample included 58 unaffected indi-
viduals and 79 individuals with DM1. The Iowa site
contributed 38 unaffected individuals and 41 indi-
viduals with DM1, and the Glasgow site contributed
20 unaffected individuals and 38 individuals with
DM1 (Table 1). The unaffected group included equal
numbers of men (n = 29) and women (n = 29), while
the DM1 group included significantly more women
(n = 50) than men (n = 29), χ2(1) = 6.0, p = 0.02. Note
that statistical models are adjusted for sex. Aver-
age age at evaluation was 46 years old (SD = 13
years), with no significant difference between groups,
t(134) = 0.5, p = 0.6. ePAL values in the DM1 group
ranged from 55 to 572 CTG repeats (Fig. 1), and
self-reported age at onset of DM1 symptoms was on
average 33 years old (SD = 12 years) (Table 1).
Brain morphology
Sex was a significant predictor of intracranial vol-
ume (ICV), with women exhibiting lower ICV than
men, t(132) = 9.6, p < 0.0001. Age did not predict ICV
(p = 0.1). The group coefficient for ICV was signifi-
cant (t(132) = –4.1, p < 0.0001), with mean ICV being
7.6% lower in the DM1 group compared with unaf-
fected individuals (Fig. 2A).
Both sex and age were significant predictors of
cerebrospinal fluid volume, t(132) = 2.8, p < 0.01, and
t(132) = 9.6,p < 0.00001, respectively. The group coef-
ficient was also statistically significant (t(132) = 3.8,
p < 0.001). Individuals affected with DM1 had
approximately 11% greater CSF volume than unaf-
fected individuals (Fig. 2A).
Compared with unaffected individuals, the DM1-
affected group exhibited significantly lower cerebral
volume (t(132) = –4.2, p < .0001), evidently driven
mostly by cerebral grey matter (t(132) = –4.4,
p < 0.0001). Cerebellar white matter was significantly
reduced in DM1 as well, t(132) = –2.7,p = 0.01. Across
cerebral lobes, the DM1 group exhibited lower vol-
ume in frontal grey (t(132) = –4.4, p < 0.0001) and
white matter (t(132) = –2.4, p = 0.02), parietal grey
matter (t(132) = –4.2, p < 0.0001), as well as corpus
callosum (t(132) = –3.5, p < 0.0001). Subcortically,
affected individuals exhibited lower volumes of puta-
men (t(132) = –2.1, p = 0.04), accumbens (t(132) = –2.3,
p = 0.03), and thalamus (t(132) = –2.8, p = 0.01). By
contrast, hippocampus (t(132) = 2.4, p = 0.02) and
amygdala volume (t(132) = 5.4, p < 0.00001) were
larger in individuals affected with DM1 (Fig. 2A
and 2B). Unadjusted parcellation volumes in these
regions also appeared larger in the DM1-affected
group prior to standardization (Supplementary Fig-
ure 3).
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Fig. 1. Distribution of CTG repeat length (expressed as ePAL) among individuals with DM1 in the sample.
Table 1
Site characteristics
Controls DM1
Scotland Iowa Scotland Iowa
Sample N 20 38 38 41
Sex N Males 12 17 17 12
Females 8 21 21 29
Age at evaluation Mean (SD) 46.1 (13.1) 44.6 (13.7) 47.1 (13.2) 45.4 (11.7)
Age at symptom onset Mean (SD) – – 30.5 (13.4) 35.4 (10.3)
Muscle impairment N MIRS 1 – – 3 12
MIRS 2 – – 6 19
MIRS 3 – – 10 5
MIRS 4 – – 18 5
MIRS 5 – – 1 0
ePAL Range – – 56–572 55–501
Median – – 211 131
Interquartile range – – 152–269 88–215
Analyses indicated a negative coefficient for
ePAL when predicting adjusted putamen vol-
ume (t(132) = –2.9, p = 0.01), occipital grey matter
(t(132) = –2.5, p = 0.01), and thalamus (t(132) = –2.0,
p = 0.05; Fig. 3). A positive ePAL coefficient was
observed for amygdala volume (t(132) = 2.2, p = 0.03),
and cerebellar white matter (t(132) = 1.98, p = 0.05)
(Fig. 3).
DISCUSSION
The present study constitutes the largest neu-
roimaging study in DM1 to date, demonstrating
that multi–site neuroimaging is a feasible, pow-
erful approach to elucidate mechanisms of CNS
disease in DM1. We restricted our sample to adult-
onset DM1 to limit confounders associated with the
markedly diverse clinical continuum, such as intel-
lectual deficits that are evident in congenital and
juvenile onset DM1 [21]. We also added a com-
prehensive, volumetric parcellation approach to the
existing literature on brain morphology in DM1, and
identified regional structural brain abnormalities in
individuals with adult-onset DM1. We demonstrated
that variation in volume of the putamen, occipital gray
matter, thalamus, and amygdala was significantly
predicted by CTG repeat expansion, strengthening
the link between regional abnormalities and disease-
specificity.
In line with earlier work [15, 36–39], we replicate
evidence of lower ICV in individuals with DM1. ICV
is considered a marker of maximal brain growth and
is largely determined by the age of 10 years, irrespec-
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Fig. 2. Structural brain differences between DM1 patients and unaffected adults. Panel A: The circles represent estimated group differences
adjusted for sex, age and site in SD units (x-axis) for regional volume (y-axis). The vertical, dashed line marks 0, i.e., no group difference.
The solid lines represent the 95% confidence limits, and the dashed lines the 99% confidence limits. Negative differences indicate that the
DM1 group had smaller volumes than did controls, while positive differences indicate that the DM1 group had larger volumes than controls.
Panel B: Summary of group differences in regional volumes between individuals with and without DM1 after ICV adjustment. The colors
correspond with the magnitude of the t-values of group differences (see color scale). Cool colors indicate that the DM1 group had lower
volume than the unaffected group, while hot colors indicate the opposite pattern.
tive of subsequent changes in the brain parenchyma
[40]. The finding of reduced ICV is therefore par-
ticularly notable in our cohort, in which recruitment
was targeted to the adult-onset form of DM1. While it
must be acknowledged that timing of onset of symp-
toms is a somewhat subjective measure, and it cannot
be excluded that some subjects could have manifested
subtle features of DM1 in childhood, this finding does
imply that presence of the expanded CTG repeat has
an effect on CNS structure prior to the onset of overt
classical DM1 symptoms.
The cause of restricted brain volume in DM1 is not
known. It could be hypothesised to result from a vari-
ety of mechanisms, including abnormal development,
differences in cell volume, reduced proliferation,
or early loss of neurons [41, 42]. In patients with
schizophrenia, who show more subtle reduction in
ICV [43], reduced grey matter volume and synaptic
density is believed to occur due to an excess of synap-
tic pruning [44], the physiological process of neural
remodelling that typically occurs from childhood
through adolescence. Early-onset, excessive pruning
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Fig. 3. Association between regional brain volume and ePAL in DM1. The circles represent estimated coefficients (circles) for the relationship
between ePAL and regional volume (y-axis), adjusted for sex, age, and site in SD units (x-axis) among individuals with DM1. The vertical,
dashed lines marks 0, i.e., no effect of ePAL. The solid lines represent 95% confidence limits, and the dashed lines represent 99% confidence
limits.
could conceivably represent an additional mechanism
affecting maximum ICV growth in DM1. Of note, it is
unclear whether the modest reduction of IQ observed
in cohorts with adult-onset DM1 entirely represents a
neurodegenerative process [45], or may have its roots
in abnormal brain development. Neurodevelopmen-
tal aspects of adult-onset DM1 therefore represent a
key area for further work to improve understanding
of CNS disease.
Regional brain volume was found to be reduced
in DM1-affected subjects, while CSF volume was
greater in the DM1 group than the unaffected group.
Studies on the aging brain or in neurodegenerative
disorders have demonstrated that atrophy coincides
with increased ventricular spaces and greater CSF
volume [46, 47]. Regional volume reductions in DM1
are thought to be the result of atrophy [10, 19], there-
fore the observed increase in CSF is to be expected.
We observed reduced volume of frontal and pari-
etal lobes, as well as substantial loss in subcortical
structures including thalamus and putamen, consis-
tent with the findings of previous studies in smaller
cohorts using alternative neuroimaging techniques
[11–13, 18]. The functional impact of structural
changes observed is not clear from the available data,
so the need to explore clinical correlations of brain
morphological abnormalities remains. The functional
impact of subcortical volume loss is of particular
interest, given the roles of these structures in main-
taining wakefulness, regulating sleep architecture,
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and in cognitive processing [48], which could clearly
be relevant to elements of the DM1 phenotype.
Variation in putamen, thalamus and occipital grey
matter volume was negatively related to the size of
the CTG repeat expansion (adjusting for covariates),
while amygdala volume was positively associated
with CTG repeat length. These results support a direct
association between these regional brain abnormal-
ities and the primary genetic lesion in DM1. The
positive association between CTG repeat length and
cerebellar white matter volume is somewhat puz-
zling, given the observation that cerebellar white
matter was significantly reduced in the DM1 group
compared with the unaffected group.
The processes by which CTG expansion leads to
structural brain change in DM1 are incompletely
understood. Histopathology studies of brain suggest
a complex phenotype, including widespread neuronal
loss, presence of neurofibrillary tangles, hyalinisation
of capillary walls and diffuse widening of perivascu-
lar spaces [49, 50]. At the cellular level, CUG repeat
mRNAs arising from the expanded repeat are seen
to form discrete foci in the nuclei of DM1-affected
neurons. Presence of these foci is associated with a
dysregulation of alternative splicing affecting a wide
range of mRNA targets [51], with the potential to
impact a range of critical pathways and structural
proteins in neural cells. For example, tau protein is
subject to a shift in alternative splicing, favoring fetal
isoforms [52]. These isoforms have lower affinity
to bind and stabilize the microtubular cytoskele-
ton, and may disrupt axonal transport. Overlapping
histological features between DM1 and Alzheimer
dementia, including presence of neurofibrillary tan-
gles, strongly supports a role of tau dysfunction in
CNS pathogenesis [53]. Evidence for dysregulated
splicing of the NMDA receptor subunit NMDAR1
[54] and altered expression of synaptic vesicle pro-
teins [55] suggest a role for disruption of synaptic
signalling also.
It is possible that different mechanisms are pre-
dominantly responsible for driving structural change
in different regions of brain, which could account
for variation in the degree of volumetric change and
strength/direction of correlations with the CTG repeat
between regions. Expansion-biased somatic instabil-
ity of the CTG repeat in DM1 varies between tissues,
and is generally seen to be greater in the tissues most
affected by the disease, such as muscle [56]. Intrigu-
ingly, in the CNS, somatic instability is comparatively
low in cerebellar cortex compared with frontal cere-
bral cortex [50], consistent with the relative severity
of volume loss observed in these structures. Fur-
ther studies of postmortem brain would be useful
to gather further evidence for variation in pathology
in different brain regions. Systematic measurement
of somatic instability in specific structures would be
particularly useful to evaluate this mechanism as a
driver of CNS pathology, and hence possible target for
therapy.
Larger volume of amygdala and hippocampus was
an unexpected finding, particularly in the context of
widespread volume loss. This observation is notable
in the context of a previous study using VBM which
reported reduced hippocampal volume in DM1 [39].
In addition to using a different parcellation approach,
the present study included a sample around five
times larger than the study by Weber and colleagues.
It should also be noted that the observed increase
in amygdala and hippocampal volumes was not an
artefact of our standardization method, as the DM1
group exhibited larger unadjusted volumes in these
regions than unaffected controls (see Supplementary
Figure 3).
The cause of increased volume is unclear, but may
relate to loss of mechanical growth restriction due
to atrophy of adjacent structures, a compensatory
change to preserve function in neuronal systems,
abnormal growth driven by the molecular pathology
of DM1, a combination of these factors, or other pro-
cesses. The limited histological evidence available
from previous studies suggest amygdala and hip-
pocampus are not spared from the disease process, in
that they exhibit typical hallmarks of DM1 including
neurofibrillary tangles [49, 57]. Interestingly, sleep
disordered breathing has been linked to both regional
increases and decreases in hippocampus volume in
non-DM1 subjects, held to represent the acute and
chronic effects of hypoxia respectively [58]. Further,
emerging evidence suggests a functional link between
amygdala and control of respiration, with stimula-
tion of the amygdala seen to induce apnea [59].
Given the high prevalence of sleep disordered breath-
ing in DM1, including presence of central apneas
[60], clinical correlations with respiratory measures
would be important to explore in future work. The
amygdalo-striatal circuitry has further been impli-
cated in motivational salience [61], raising questions
about the potential role of amygdalo-striatal dys-
function in symptoms of depression, apathy, and
anhedonia that are commonly observed among indi-
viduals with DM1 [62]. Current efforts to develop
therapy for anxiety disorders, through manipula-
tion of specific inhibitory neuron populations within
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the amygdala [63], could therefore yield useful
therapeutic targets for a range of CNS symptoms
in DM1.
A limitation of the present study is that volumet-
ric analysis gives limited information regarding the
structural or functional integrity of white matter. In
contrast to some previous data [11], we found that vol-
umetric changes were generally less marked in white
matter structures compared with associated grey
matter. Nonetheless, white matter pathology clearly
represents an important component of the CNS struc-
tural landscape in DM1, as evidenced by the frequent
occurrence of T2 hyperintense lesions [10], and
widespread reduced fractional anisotropy on diffu-
sion tensor imaging, even in normal-appearing white
matter [64]. It remains uncertain to what extent white
matter disease represents a primary manifestation of
the DM1 disease process, versus Wallerian degenera-
tion secondary to loss of associated grey matter [16].
Given that a number of disease processes likely con-
spire to cause structural brain changes in DM1, it is
clear that a range of modalities should be employed
in future neuroimaging studies. Future studies would
also benefit from a longitudinal design. Of note,
recent data from Gliem and colleagues [65] sug-
gest the rate of structural brain change over time
may be slow, and hence could be challenging to
measure within the timescale of a typical clinical
trial. Further, respiratory function was not specifically
assessed as part of the present study. Sleep-disordered
breathing is common in DM1 [66], and has been
linked to various structural brain changes in other
patient populations [58, 67, 68], therefore detailed
phenotyping of respiratory function including sleep
studies should be considered as part of future neu-
roimaging work. Finally, the clinical impact of the
structural changes identified were not explored as
part of the present study. Correlation of structural
measures with neuropsychological data would be an
important extension of the work presented here, to
identify how abnormal brain structure may relate to
functional problems.
In summary, the present study highlights the poten-
tial for multi-site neuroimaging efforts to elucidate
neuropathological features associated with inherited,
rare neurological disorders, such as DM1. The pooled
sample represents the largest case-control DM1 neu-
roimaging cohort at present. The study provided
novel insights into the effects of DM1 on the human
brain, by providing a detailed portrait of the rela-
tive volumetric changes occurring in specific regions.
Several of the structural changes were directly cor-
related with CTG repeat length, and occurred in
structures with potential functional links to key
features of the DM1 phenotype. These findings illu-
minate potential avenues for further research work
to elucidate the molecular and neuroanatomical basis
for central symptoms in DM1.
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